• Death receptor 6 ( DR6 ), also known as tumor necrosis factor receptor superfamily member 21 ( TNFRSF21 ), is a cell surface receptor of the tumor necrosis factor receptor superfamily which activates the JNK and NF-κB pathways. (wikidoc.org)
  • The ligand is specific for the 4-1BB RECEPTOR and may play a role in inducing the proliferation of activated peripheral blood T-LYMPHOCYTES. (rush.edu)
  • The most common example of this type of fusion protein combines the hinge and Fc regions of an immunoglobulin (Ig) with domains of a cell-surface receptor that recognizes a specific ligand (Box 1). (coek.info)
  • The CD27 antigen is a lymphocyte-specific member of the tumor necrosis factor receptor (TNFR) super family, which also includes nerve growth factor receptor, CD30, CD40, CD95 (Fas), CD120a, CD120b, CD134 (OX 40), and CD137. (bdbiosciences.com)
  • CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-κB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-κB-inducing kinase. (bdbiosciences.com)
  • Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. (bdbiosciences.com)
  • [2] The DR6 is an alpha-helical integral membrane receptor protein that shows evidence that it has something to do with the inhibition of blood vessels forming on tumors which would allow them to grow larger. (wikidoc.org)
  • The secreted extracellular form is a weak inducer of APOPTOSIS for some cell types and a ligand for the FN14 RECEPTOR. (uchicago.edu)
  • Finally, the Tumor Necrosis Factor Receptor Family include immune checkpoint molecules such as CD27, tumor markers such as CD30, and co-stimulatory molecules such as CD40. (pharna.com)
  • A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. (childrensmercy.org)
  • A membrane-bound tumor necrosis family member found primarily on activated T-LYMPHOCYTES that binds specifically to CD30 ANTIGEN. (wakehealth.edu)
  • A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN . (nih.gov)
  • Together these data support the ability of brentuximab vedotin and MMAE to drive ICD in tumor cells resulting in the activation of antigen-presenting cells and augmented T-cell immunity. (bvsalud.org)
  • However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of relapses present a tumor phenotype with retention of target antigen (antigen-positive relapse), which highly correlate with poor CAR T cells persistence. (biomedcentral.com)
  • Human derived T lymphocytes engineered to express chimeric antigen receptors, which are expanded in vitro culture and then infused into patients exerting robust cytotoxicity after tumor antigen recognition and subsequent activation. (biomedcentral.com)
  • A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes. (lookformedical.com)
  • B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. (lookformedical.com)
  • The protein has no known natural ligand [4] and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. (wikidoc.org)
  • Cytokines are a family of cell signaling proteins that include Chemokines, Interleukins, Tumor Necrosis Factors (TNFs), Transforming Growth Factors (TGFs), Inter ferons, and Colony Stimulating Factors (CSFs). (pharna.com)
  • Therefore, study on factors and mechanisms that limit the in vivo persistence of CAR T cells is crucial for developing strategies to reduce the probability of tumor relapse and improve the long-term disease-free survival for patients who are treated with CAR T cells. (biomedcentral.com)
  • Receptors, Tumor Necrosis Factor, Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (childrensmercy.org)
  • This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type I" was a major or minor topic of these publications. (childrensmercy.org)
  • Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type I" by people in Profiles. (childrensmercy.org)
  • Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. (bdbiosciences.com)
  • B7-H4 is an immune checkpoint ligand with elevated expression on a variety of solid tumors, including breast, ovarian, and endometrial tumors, and limited normal tissue expression. (bvsalud.org)
  • CONCLUSION: The immune checkpoint ligand B7-H4 is a promising molecular target expressed by multiple solid tumors. (bvsalud.org)
  • Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
  • A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. (lookformedical.com)
  • In vivo, SGN-B7H4V demonstrated strong antitumor activity in multiple xenograft models of breast and ovarian cancer, including xenograft tumors with heterogeneous B7-H4 expression, consistent with the ability of vedotin ADCs to elicit a bystander effect. (bvsalud.org)
  • Brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), is approved for clinical use in multiple CD30-expressing lymphomas. (bvsalud.org)
  • The ability of SGN-B7H4V to kill B7-H4-expressing tumor cells in vitro and in vivo in a variety of xenograft tumor models was also evaluated. (bvsalud.org)
  • In vitro, SGN-B7H4V killed B7-H4-expressing tumor cells by MMAE-mediated direct cytotoxicity and antibody-mediated effector functions including antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. (bvsalud.org)
  • Finally, the antitumor activity of SGN-B7H4V as monotherapy and in combination with an anti-programmed cell death-1 (PD-1) agent was evaluated using an immunocompetent murine B7-H4-expressing Renca tumor model. (bvsalud.org)
  • In an immunocompetent murine B7-H4-expressing tumor model, SGN-B7H4V drove robust antitumor activity as a monotherapy that was enhanced when combined with an anti-PD-1 agent. (bvsalud.org)
  • Progressive biliary destruction is independent of a functional tumor necrosis factor-alpha pathway in a rhesus rotavirus-induced murine model of biliary atresia. (childrensmercy.org)
  • This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. (lookformedical.com)
  • Altogether, these preclinical data support the evaluation of SGN-B7H4V as a monotherapy in the ongoing phase 1 study of SGN-B7H4V in advanced solid tumors (NCT05194072) and potential future clinical combinations with immunotherapies. (bvsalud.org)
  • It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. (childrensmercy.org)
  • [15] In cases of obesity , the presence of fatty tissues surrounding the body's major organ systems results in cell necrosis and insulin desensitivity along the boundary between them. (wikidoc.org)
  • The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
  • Tumor cells can induce, through exposition of amyloid precursor protein (APP), DR6-mediated endothelial cell necroptosis allowing tumors metastasis. (wikidoc.org)
  • in addition, T cells transferred from previously vaccinated animals slowed tumor growth in immunodeficient mice. (bvsalud.org)
  • In a humanized model of CD30+ B cell tumors, treatment with brentuximab vedotin drove the expansion and recruitment of autologous EBV-reactive CD8+ T cells potentiating the activity of anti-PD-1 therapy. (bvsalud.org)
  • [8] APP ( amyloid precursor protein ) is the natural ligand of DR6 and is first cleaved into Aβ and N-APP. (wikidoc.org)
  • The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. (lookformedical.com)
  • 17. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. (nih.gov)
  • Incorporation of a single chain variable fragment (scFv) of a tumor antigen specific antibody and signaling domains of T cell receptor (TCR) renders chimeric antigen receptor (CAR) the specificity of antibody as well as the cytotoxicity of cytotoxic T lymphocytes (CTLs) [ 1 ]. (biomedcentral.com)
  • The formation of the signal-transducing complex of each cytokine depends on specific ligand and receptor association. (frontiersin.org)
  • A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. (uchicago.edu)
  • TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. (uchicago.edu)
  • A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. (rush.edu)
  • It is most closely related to TNF R1 and FAS/CD95, sharing 29% and 23% aa sequence identity, respectively. (rndsystems.com)
  • Clinical application of PDGF is being investigated after it has been recently found that the molecule is involved in atherosclerosis as well as angiogenesis and metastasis of solid tumors. (fujifilm.com)
  • Many advances have been reported regarding the outcomes of these early clinical studies (Phase I/II) including the effect on hematological malignancies and some solid tumors. (biomedcentral.com)
  • 9. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma. (nih.gov)
  • 10. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. (nih.gov)
  • Identification of pathogenic variants in genes relevant for the Fas pathway of apoptosis. (nih.gov)
  • However, in a tumor cell line, TF-1, TL1A has been shown to induce caspase activity and apoptosis. (rndsystems.com)
  • For example, the soluble receptors of TNF-α and IL-1α act as antagonists by neutralizing and inhibiting the activity of their ligands ( 17 - 19 ). (frontiersin.org)
  • 4. Regulation of immune responses by the ligands for CD27, CD30, and 4-1BB. (nih.gov)
  • 11. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. (nih.gov)
  • 15. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. (nih.gov)
  • 1. Expression and function of CD30 on T lymphocytes. (nih.gov)
  • Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. (uchicago.edu)
  • 13. The role of CD30 in the pathogenesis of haematopoietic malignancies. (nih.gov)
  • CD154 , takođe poznat kao CD40 ligand ili CD40L, je protein koji je prvenstveno izražen u aktiviranim T ćelijama . (wikipedia.org)
  • 16. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications. (nih.gov)
  • In ALPS-FAS caused by homozygous or compound heterozygous ( biallelic ) pathogenic variants in FAS , severe lymphoproliferation occurs before, at, or shortly after birth, and usually results in death at an early age. (nih.gov)
  • Future directions include optimizing the lymphodepletion regimen, enhancing migration to the tumor site, and combination with other immune regulators. (biomedcentral.com)
  • TL1A/VEGI, a TNF superfamily ligand, has been shown to bind and activate DR3 (8). (rndsystems.com)
  • 5. In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. (nih.gov)
  • In the present study, we analyzed and identified novel B[a]P-associated circular RNA (circRNA) from microarray databases of liver tumor cells and HCC patient samples. (bvsalud.org)
  • Furthermore, up-regulated circ_0084615 in B[a]P-treated tumor cells was verified as a miRNA sponge via fluorescence in situ hybridization (FISH) assays, and the repression between circ_0084615 and target miR-451a exhibited a contrasting effect on hepatocarcinogenesis. (bvsalud.org)
  • Preclinical studies with CD30-directed CAR-T cells support the feasibility of this approach. (biomedcentral.com)
  • Recently, two clinical trials of CD30-directed CAR-T cells in relapsed/refractory CD30+ lymphomas, including Hodgkin lymphoma, have been reported with minimal toxicities noted and preliminary efficacy seen in a proportion of patients. (biomedcentral.com)
  • Several ongoing and upcoming clinical trials of CD30-directed CAR-T cells are expected to further enhance this approach to treat patients with relapsed and refractory CD30+ lymphomas. (biomedcentral.com)
  • 19. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. (nih.gov)
  • Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report. (ouhsc.edu)
  • These genes include FAS (either germline or somatic pathogenic variants), CASP10 , and FASGL . (nih.gov)